2021

Novel Research Paves Way for Better Optimization of Daratumumab Treatment for NK/T lymphoma Patients

September 9, 2021

Natural Killer T cell lymphoma (NKTL) is a highly aggressive form of cancer more frequently occurring in Asia than other parts of the world with very poor treatment outcomes in the advanced stages. Currently, there is still no clear consensus on primary therapy, and chemoradiation or L-Asparaginase therapy remain mainstay treatments. Hence, novel and effective treatment strategies are needed. Daratumumab is a monoclonal antibody that is utilised in cancer treatment to specifically target the CD38 protein on malignant cells.

Read More
Sep 09, 2021 Celine Tam 0 comments
Ms Sinan Xiong Receives the IMS Young Investigator Award for Exemplary Abstract

September 8, 2021

Congratulations to Ms Sinan Xiong for receiving the IMS Young Investigator Award at the 18th International Myeloma Workshop (IMW 2021). The workshop is conducted by the International Myeloma Society (IMS), which aims to promote research and education to improve prevention, diagnosis, prognosis, and treatment surrounding multiple myeloma and related disorders.

Read More
Sep 08, 2021 C K Sangamitha 0 comments
Sep 07, 2021 Celine Tam 0 comments
Virtual Graduation Celebration for the Graduating Classes of 2020 and 2021

September 3, 2021

Congratulations to the graduates of the PhD Graduate Program in Cancer Biology! On 27th August 2021, CSI Singapore organized a virtual Graduation Celebration to honour the Classes of 2020 and 2021. While COVID-19 has certainly been disruptive, our graduates have demonstrated adaptability and resilience amid the uncertainties of the pandemic. The virtual celebration was also attended by supervisors of the graduating batches, where they paid tribute to the amazing achievements of our graduates after years of hard work and commitment.

Read More
Sep 03, 2021 Celine Tam 0 comments
Determinants of Response to Daratumumab in Epstein-Barr Virus-Positive Natural Killer and T-Cell Lymphoma. (J Immunother Cancer, Jul 2021)

August 31, 2021

This study characterizes CD38 as an effective target for a subset of NKTL patients and the utilization of the CD38:CIP ratio as a more robust identifier for patient stratification and personalisation of treatment. Furthermore, elucidation of factors which sensitize the complement-mediated response provides an alternative approach toward optimizing therapeutic efficacy of daratumumab where CDC remains a known limiting factor.

Read More
Aug 31, 2021 Celine Tam 0 comments
Chromatin Interaction Neural Network (ChINN): A Machine Learning-Based Method for Predicting Chromatin Interactions from DNA Sequences. (Genome Biol, Aug 2021)

August 31, 2021

Chromatin interactions play important roles in regulating gene expression. However, the availability of genome-wide chromatin interaction data is limited. We develop a computational method, chromatin interaction neural network (ChINN), to predict chromatin interactions between open chromatin regions using only DNA sequences.

Read More
Aug 31, 2021 Celine Tam 0 comments
Repurposing RNA Sequencing for Discovery of RNA Modifications in Clinical Cohorts. (Sci Adv, Aug 2021)

August 31, 2021

The study of RNA modifications in large clinical cohorts can reveal relationships between the epitranscriptome and human diseases, although this is especially challenging. We developed ModTect (https://github.com/ktan8/ModTect), a statistical framework to identify RNA modifications de novo by standard RNA-sequencing with deletion and mis-incorporation signals.

Read More
Aug 31, 2021 Celine Tam 0 comments
CSI Director Shares His Thoughts on Building a Great and Inclusive Workplace

August 23, 2021

CSI Singapore Director, Prof. Ashok Venkitaraman, recently shared his experiences and aspirations for inclusive and equitable policies and practices in the workplace during the NUHS Women in Science and Healthcare (WISH) Lunch & Learn series which was held on 30th June 2021.

Read More
Aug 23, 2021 Celine Tam 0 comments
CSI Singapore Receives NUS Safety & Health Commendation Award

August 6, 2021

We are pleased to announce that CSI Singapore has been conferred the Commendation Award for the NUS Safety & Health Awards (NUSSHA) 2020! Presented by the Office of Safety, Health & Environment (OSHE), the NUSSHA programme recognizes NUS Faculties, Departments, and Research Centres / Research Institutes which have implemented effective department safety and health management system (DSHMS) that would help reduce accidents and incidents in workplaces.

Read More
Aug 06, 2021 Celine Tam 0 comments
CSI Singapore Conferred Multiple Awards at NCIS Annual Research Meeting (NCAM 2021)

August 4, 2021

Hosted by the National University Cancer Institute, Singapore (NCIS) and co-organized by the Cancer Science Institute of Singapore (CSI), the 8th NCIS Annual Research Meeting (NCAM) concluded its hybrid meeting last Saturday. Held from 30 - 31 July, this year's meeting served as an excellent platform for cancer physicians and researchers in Singapore to interact and forge future collaborations.

Read More
Aug 04, 2021 Celine Tam 0 comments
Prof. Chng Wee Joo Receives Yong Loo Lin School of Medicine Graduate Mentor of the Year (GRAMAY) Award 2021

June 10, 2021

Congratulations to CSI Deputy Director and Senior Principal Investigator, Prof. Chng Wee Joo, on being conferred the Yong Loo Lin School of Medicine Graduate Mentor of the Year (GRAMAY) 2021! Presented annually, the GRAMAY award honors and celebrates faculty staff in recognition of their excellence in graduate supervision, intellectual and professional development as well as career development of their graduate students.

Read More
Jun 10, 2021 Celine Tam 0 comments
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

June 4, 2021

WILMETTE, Ill., June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has entered into a collaboration agreement with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer.

Read More
Jun 04, 2021 Celine Tam 0 comments
Congratulations to Dr. Polly Chen on her promotion to Associate Professor!

May 12, 2021

CSI Singapore is proud to announce the promotion of Dr. Polly Chen to Associate Professor! Dr. Chen joined CSI Singapore in 2014 as a Principal Investigator. Since then, she has received multiple awards in recognition of her outstanding research, including the EMBO Young Investigator Program (YIP) and the Yong Loo Lin School of Medicine Young Researcher Of the Year Award.

Read More
May 12, 2021 Celine Tam 0 comments
Cancer drug may be able to treat inflammation caused by COVID-19 virus, Singapore-US study shows

April 13, 2021

CSI Principal Investigator, Dr. Anand Jeyasekharan, was recently involved in a pioneering study performed by the Icahn School of Medicine at Mount Sinai in the United States and the National University Cancer Institute, Singapore (NCIS). Findings from this study revealed that Topotecan, a chemotherapeutic drug, can reduce the severity and death rates of infection by SARS-CoV-2 and may potentially be used to treat patients with moderate to severe forms of Covid-19.

Read More
Apr 13, 2021 Celine Tam 0 comments